DocWire News Editors

DocwireNews

In older adult Medicare beneficiaries with CLL, treatment with ibrutinib was associated with a nearly threefold increased risk of atrial fibrillation (AF), according to study findings presented at the 62nd American Society of Hematology Annual Meeting &amp; Exposition.The study was presented by Akiva Diamond, MD, of the Baylor St. Luke&rsquo;s Medical Center in Houston. Dr. Diamond explained that he and his colleagues conducted an analysis of the SEER-Medicare database to identify Medicare beneficiaries aged 66 years and older with CLL. Medicare Part B and D data were used to identify which treatments were used for these patients. The primary outcomes of the analysis were AF and stroke.Approximately 6% (n=299) of the 4,958 patients with CLL in the SEER-Medicare database were treated with ibrutinib. The median age in the ibrutinib-treated population was 75 years, and the majority of these patients were white (90.3%).In the 2,169 patients with CLL who were never treated, the stroke incidence was 11.9% following CLL diagnosis (incidence rate, 47.7/1,000 person-years), whereas the incidence of AF was 15.2% (60.6/1,000 person-years).The incidence rates of stroke and AF among patients treated with an agent other than ibrutinib were 54.69/1,000 and 67.2/1,000 person-years, respectively. In contrast, the incidence rate of AF was 221.8/1,000 person-years, and the incidence rate of stroke was 72.9/1,000 person-years among patients treated with ibrutinib.In an analysis that adjusted for potential confounders, the risk of AF was threefold higher for patients treated with ibrutinib compared with patients who received a different therapy (hazard ratio [HR], 3.0; 95% confidence interval [CI], 2.1-4.4). No similar association was found between treatment with ibrutinib compared with another treatment in terms of stroke risk (HR, 1.1; 95% CI, 0.48-2.3).In their abstract, the researchers wrote that future analyses should examine the risk of other complications in patients with versus without CLL. They added that further studies should look at the correlation between complications and the treatment of widespread Bruton&rsquo;s tyrosine kinase inhibitor use, among other targeted treatments for CLL.

Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

Ibrutinib-Treated Older Patients with CLL Have Threefold Higher Risk of AF

ASH Annual Meeting 2020

In older adult Medicare beneficiaries with CLL, treatment with ibrutinib was associated with a nearly threefold increased risk of atrial fibrillation (AF), according to study ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe